Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2024

Genmab — Februar 2024

Planlagt Fastgjort Låst Flyttet Genmab
1.6k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #72

    Lidt om penpulimab der er en PD1 IgG1 checkpoint inhibitor

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #73

      Akeso Biopharma is the producer, chinese https://www.akesobio.com/en/rd-and-science/products-center/

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #74

        i get 54 hits on clinicaltrials with that drug...

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #75

          would be nice to know if that really is a new GEN1056 trial; it would mean the correct dosing is known i guess. Primary Completion (Estimated) for the safety trial is

          2024-02-15 so that would be possible.

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #76

            Biotech boom ahead in 2024, top Jefferies analyst predicts https://proinvestor.com/boards/118515

            1 Reply Last reply
            0
            • R Offline
              R Offline
              Raun
              wrote on sidst redigeret af
              #77

              Lad os håbe at de kloge får ret denne gang.... De sagde også sidst i 2022, at pharma og biotec vil blive det hotteste i 2023..... Øøh - det var nok blevet for varmt! 😉

              1 Reply Last reply
              0
              • J Offline
                J Offline
                JKY_VH
                wrote on sidst redigeret af
                #78

                Gad vide, hvad der ville ske, hvis Jan laver en Meta i næste uge? https://finans.dk/erhverv/ECE16815769/mark-zuckerberg-staar-til-at-tjene-milliarder-paa-sin-egen-nyhed/?utm_campaign=FINANS Briefing&utm_content=2024-02-05&utm_medium=email&utm_source=finans

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #79

                  @Bulder i don't think we will see a '..mab' anymore, there is new Nomenclature . If i am correct, for erzotabart it is ta for tumor and bart for artificial antibody https://en.wikipedia.org/wiki/Nomenclature_of_monoclonal_antibodies

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #80

                    Ok, thx

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #81

                      So in cancer antibodies will all be named …tabart with different prefix?

                      1 Reply Last reply
                      0
                      • JørgenVarnæsJ Offline
                        JørgenVarnæsJ Offline
                        JørgenVarnæs
                        wrote on sidst redigeret af
                        #82

                        thanks for a very useful link EL - I guess the "ta" is for both solid and liquid tumors?

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #83

                          no i am not sure it will Bulder, for example i think they may use -mig for a bispecific monoclonal antibody (BsMAb) and maybe a cancer drug can also fall under immunomodulating?

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #84

                            yea that would be my guess too JV

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #85

                              Yes you are right, -pru- and -sto- could also be possible.

                              1 Reply Last reply
                              0
                              • FrittenF Offline
                                FrittenF Offline
                                Fritten
                                wrote on sidst redigeret af
                                #86

                                Novo køber fabrikker - Kursen stiger, Genmab købte fabrik og kursen faldt. Novo hæver deres omkostninger til udvikling, kursen stiger, Genmab hæver deres omk til udvikling og kursen falder. Jeg giver snart op;-)

                                1 Reply Last reply
                                0
                                • J Offline
                                  J Offline
                                  JKY_VH
                                  wrote on sidst redigeret af
                                  #87

                                  Lyder da meget nemt;-)

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #88

                                    i think Catalent also produces Tepezza

                                    1 Reply Last reply
                                    0
                                    • R Offline
                                      R Offline
                                      Raun
                                      wrote on sidst redigeret af
                                      #89

                                      Et rædsels år for Genmab aktien, må vi bare konstaterer at 2023 var. - Nok mest tynget af voldgift sagen.... Nu er jeg godt nok bange for at vi er ude i en double jeopardy på Genmab kursen, frem imod en eventuel opt.in.... Det er slet ikke rart at se, at NBI er oppe med 10% siden november og andre succesfulde pharma og biotek selvskaber stormer frem....

                                      1 Reply Last reply
                                      0
                                      • JørgenVarnæsJ Offline
                                        JørgenVarnæsJ Offline
                                        JørgenVarnæs
                                        wrote on sidst redigeret af
                                        #90

                                        Ptjah - evnen til at forære verdensklasse medikamenter væk er vist den sande KYSO i Genmab

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #91

                                          Jeg forstår slet ikke I er aktionærer i Genmab ?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper